Abstract 3781
Background
SD-101 is a synthetic CpG-ODN agonist of TLR9. Pembrolizumab is an antibody to PD-1. DV3-MEL-01 (SYNERGY-001) assesses the safety and preliminary efficacy of the combination of SD-101 and pembrolizumab in stage IIIC-IV melanoma.
Methods
Phase 1b evaluated SD-101 at multiple doses injected in a single tumor Q1W x 4 then Q3W x 7 in combination with a fixed dose of pembrolizumab (200 mg IV Q3W). Phase 2 is evaluating SD-101 at 8 mg in 1 lesion and 2 mg/lesion in 1-4 lesions. Patients were eligible if their tumor progressed on or after prior anti-PD-1 therapy. Scans are performed every 64 days. Per-protocol overall responses (ORR) were assessed per investigator using RECIST v1.1/irRECIST. The modified intent-to-treat (mITT) population included all patients except those on study who had not reached the Day 64 scan. PFS rate was calculated using the mITT population. The per-protocol population comprised patients who received at least 1 dose of each drug and had ≥1 post baseline scan.
Results
38 patients enrolled: median age 64 years; male 74%; ECOG PS 0 58%; Stage IIIC 32%, IVM1a/b 13%, Stage IVM1c/d 50%; LDH > ULN 39%. SD-101 safety profile consists of transient, mild-to-moderate flu-like symptoms and injection-site reactions. Grade 3-4 treatment-related AEs = 32%. Immune-related AEs (irAEs) = 5%. ORR (mITT) = 16% (6/37) (CR 3%/PR 14%/SD 30% [DCR = 46%]/PD 38%/NE 16%). Evaluable ORR =19% (6/31). 7 pts were not evaluable: on study but no Day 64 scan yet (n = 1), AE (n = 1), clinical PD (n = 2), withdrew consent/unknown (n = 3). 2 of 8 patients who began combination therapy within 3 months of starting anti-PD-1 therapy had responses including 1 CR. Median DOR not reached (range 9 weeks, 45 weeks). Median follow up = 13 weeks (range 6, 45 weeks). 6 month PFS rate = 16%. One third of the patients currently have biomarker assessments demonstrating a broad increase in TILs in patients with responses with ≥ 3 fold increase in T cells.
Conclusions
The combination of SD-101 and pembrolizumab induced responses in some patients who developed progressive disease on or after prior anti-PD-1 therapy. The combination is well tolerated with no evidence of an increased rate of irAEs.
Clinical trial identification
NCT02521870.
Legal entity responsible for the study
Dynavax Technologies Corporation.
Funding
Dynavax Technologies Corporation.
Editorial Acknowledgement
Disclosure
A. Ribas: Consulting fees: Dynavax Technologies. C. Lao: Research funding: Merck. A. Amin: Honoraria, Speaker’s bureau: Merck & Co. M. Milhem: Advisory board: Blueprint Medicines GIST. S. Chandra: Membership on advisory boards and/or Speaker's Bureau Member: EMD Serono, Bristol-Myers Squibb, Array BioPharma, Regeneron. E.V. Schmidt: Employee: Merck. R. Janssen: Employee: Dynavax Technologies Corporation; Shareholder: Dynavax and Merck stock. All other authors have declared no conflicts of interest.
Resources from the same session
4162 - ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer
Presenter: Anu Moilanen
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3747 - HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch.
Presenter: Roman Dubianski
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4688 - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four Consensus Molecular Subtypes.
Presenter: Pietro Paolo Vitiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
498 - Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Presenter: Xiao Fu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3731 - Effect of the polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in Mediterranean women
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1215 - Cisplatin in NIPEC or HIPEC?
Presenter: Ivan Alvovsky
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2738 - Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment
Presenter: MARIKO HIRAI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2190 - Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis
Presenter: Priya Sriskandarajah
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4482 - Functional inhibition of TGF-_ in colorectal cancer cells and its interaction with AXL receptor
Presenter: Davide Ciardiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
624 - Isoform-specific AKT Inhibition Differentially Affects Cell Functions in Pancreatic Adenocarcinoma
Presenter: Hugo Arasanz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract